Descripción del proyecto
Nuevo radiotratanóstico multifuncional basado en complejos supramoleculares
El radiotratanóstico es un campo emergente de la medicina nuclear que permite la obtención simultánea de imágenes y el tratamiento mediante la administración de radiación dirigida a los núcleos celulares para inducir la muerte celular. Normalmente se basa en radiofármacos inyectables en forma de moléculas individuales que incorporan un radioisótopo terapéutico o de diagnóstico. El equipo del proyecto SMARTdrugs, financiado por el CEI, pretende aprovechar el potencial extraordinario de la química supramolecular para desarrollar una nueva clase de radiotratanóstico multifuncional. El equipo pretende crear estos fármacos radiotratanósticos supramoleculares mediante el autoensamblaje de complejos de coordinación supramoleculares huésped-huésped y utilizando moléculas entrelazadas de forma molecular como matrices. En un principio se orientarán al cáncer, pero los resultados serán relevantes para otras aplicaciones de administración de fármacos y útiles para la investigación básica de las interacciones biológicas.
Objetivo
From diagnostic applications in the quantification and characterisation of biomarker expression in cancer patients, through to molecularly targeted radionuclide therapy, radiopharmaceuticals are at the frontline of modern personalised medicine. The radical long-term vision of SMARTdrugs is to harness the untapped potential of supramolecular chemistry to create a new class of therapies - radiotheranostics - which combine both diagnostic and therapeutic radionuclides in one compound. By using the self-assembly of host-guest supramolecular coordination complexes and molecularly interlocked molecules as scaffolds for creating supramolecular radiotheranostic drugs, new methods for radiotheranostic synthesis that break away from conventional medicinal chemistry concept will be introduced. SMARTdrugs will establish a proof-of-concept demonstrating the utility of non-covalent systems in the design of multifunctional radiotheranostic agents with tailored pharmacokinetics, and their application in challenging drug-delivery scenarios including targeted delivery to cancers of the lung and brain.
Our 3 main objectives:
Objective 1 – Develop new chemical landscapes using non-covalent bonding to create functionalised supramolecular compounds for cancer-specific theranostics
Objective 2 – Elucidate the key relationships between supramolecular radiotheranostics and the complex tumour microenvironment that determine drug efficacy in vivo
Objective 3 – Perform head-to-head studies to establish a proof-of-principle that supramolecular chemistry is a viable alternative to classical radiopharmaceutical design
The long-term goal is to establish a new chemical landscape for radiotheranostic design, and to facilitate clinical translation of this new technology. Successful experiments will lay the foundations for exploiting supramolecular chemistry in the wider context of drug delivery and theranostics, and for studying biological interactions at the cellular to whole-organism levels.
Ámbito científico
- medical and health sciencesbasic medicinemedicinal chemistry
- natural scienceschemical sciencesnuclear chemistryradiochemistry
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencesbiological sciencesbiological behavioural sciencesethologybiological interactions
Palabras clave
Programa(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Convocatoria de propuestas
HORIZON-EIC-2023-PATHFINDEROPEN-01
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-EIC - HORIZON EIC GrantsCoordinador
80333 Muenchen
Alemania